Most likely
B+
Bull case
78%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
OGN
OrganonANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexB
Base case
12%
Probability
Target price
$13.70
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
B-
Bear case
10%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-21
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+52.8
Score
AI commentary
Recent MIUDELLA news is constructive, but the dominant stock signal remains the narrow spread to the $14 cash offer. Organon suspended customary quarterly earnings releases and calls while the merger is pending [#SEC-8K-2026-07-31]. No reliable current analyst-revision series, measured sentiment series, options skew, short-interest figure, or employee score was supplied; zero-valued numeric sentiment fields are unavailable placeholders, not observed readings. The stored earnings-document row concerns Cooper Companies, not Organon, and was excluded.
RankAlpha Sentiment Codex - 2026-10-21
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystMIUDELLA commercial availabilityMedium impact
Organon anticipates late-2026 availability of its licensed hormone-free IUD. Launch timing and REMS enrollment are operating checks, but the fixed cash offer limits likely share-price upside [#PR-2026-09-14] [#PR-2026-10-16].
2026-12-31catalystNexplanon reinsertion-demand trendMedium impact
The June-quarter filing reported Nexplanon sales down 12% in the first half, partly because five-year label approval delayed reinsertions. Organon expected the expanded label to begin offsetting that headwind in the second half; evidence of recovery would be an operating check rather than a reason to exceed the cash offer [#10-Q-2026-07-31].
2027-03-31eventSun Pharma merger clearance and closingMedium impact
The signed transaction provides $14.00 cash per share and targets an early-2027 close. Organon shareholders approved it July 23; regulatory approvals and other closing conditions remain. From the October 20 $13.76 anchor, gross completion upside is about 1.7% before time value, while a failed deal could cause a much larger loss [#10-Q-2026-07-31] [#PR-2026-04-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-21 • Updated nightlySource: Internal modelMethodology